Search Results - "Kieseier, B.C"

EP 12. Fingolimod promotes nerve regeneration by modulating Lysophospholipid signaling by Szepanowski, F, Steiner, I, Derksen, A, zu Hörste, G. Meyer, Daldrup, T, Hartung, H.- P, Kieseier, B.C

“…The lysophospholipids sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA) are pleiotropic signaling molecules with a broad range of physiological…”
Get full text

EP 41. Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathies by Stettner, M, Hinrichs, L, Guthoff, R, Bairov, S, Petropoulos, I.N, Warnke, C, Hartung, H.-P, Malik, R.A, Kieseier, B.C

“…Objective There is an unmet need for better diagnostic tools to further delineate clinical subsets of heterogeneous chronic inflammatory demyelinating…”
Get full text

TLR 3 ligand poly I:C does not induce encephalitogenic T cells nor essentially alter cytokine production in SJL EAE by Hofstetter, H.H, Zimmermann, C, Weber, A, Kieseier, B.C, Hartung, H.P

Get full text

Clinical consequences of persistently high-titer neutralizing antibodies in patients with multiple sclerosis — /INS;Results from the German reference lab by Menge, T, Hartung-Neumann, G, Hess, A, Hartung, H.-P, Kieseier, B.C

Get full text

Natalizumab long-term therapy for relapsing MS in clinical routine: Final results of the prospective observational multicenter study Tysabri® 24 plus by Maeurer, M, Wiendl, H, Heesen, C, Gass, A, Wernsdoerfer, C, Kieseier, B.C, Zingler, V.C, Wettmershausen, C

Get full text

Polyclonal immunoglobulins (IVIg) induce expression of MMP-9 in microglia by Pul, R, Kopadze, T, Skripuletz, T, Voss, E.V, Kieseier, B.C, Stangel, M

“…Abstract In multiple sclerosis (MS) matrix metalloproteinases (MMP) are believed to be involved in the disruption of the blood brain barrier and demyelination…”
Get full text

Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study by Kieseier, B.C, Sahraian, M.A, Coles, A.J, Hartung, H.P, Havrdova, E, Selmaj, K.W, Margolin, D.H, Palmer, J, Oyuela, P

“…Background/objectives Alemtuzumab is approved in over 30 countries for relapsing-remitting multiple sclerosis. In the 2-year, phase 3 CARE-MS II study…”
Get full text

2PS2.3 New treatments for autoimmune disorders by Kieseier, B.C.

Get full text

Fatal PML associated with efalizumab therapy: Insights into integrin αLβ2 in JC virus control by SCHWAB, N, ULZHEIMER, J. C, BRÜCK, W, TOYKA, K. V, RANSOHOFF, R. M, WIENDL, H, FOX, R. J, SCHNEIDER-HOHENDORF, T, KIESEIER, B. C, MONORANU, C. M, STAUGAITIS, S. M, WELCH, W, JILEK, S, DU PASQUIER, R. A

“…Progressive multifocal leukoencephalopathy (PML) has become much more common with monoclonal antibody treatment for multiple sclerosis and other…”
Get full text

Multiple sclerosis - a dynamic field with a need for excellent education by Kieseier, B.C.

Get full text

Statins as immunomodulators: Comparison with interferon-β1b in MS by NEUHAUS, O, STRASSER-FUCHS, S, FAZEKAS, F, KIESEIER, B. C, NIEDERWIESER, G, HARTUNG, H. P, ARCHELOS, J. J

Get full text

Leukocytes in neuronal ceroid-lipofuscinoses: function and apoptosis by Kieseier, B.C., Wisniewski, K.E., Park, E., Schuller-Levis, G., Mehta, P.D., Goebel, H.H.

“…The neuronal ceroid-lipofuscinoses (NCL) are a group of progressive encephalopathies with a fatal course that are mostly of autosomal recessive inheritance…”
Get full text

Modulation von Disintegrinen durch IFN β-1b: Ein Beitrag zur Neuroprotektion? by Dehmel, T., Kieseier, B.C.

Get full text

P045 - Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study by Kieseier, B.C., Sahraian, M.A., Coles, A.J., Hartung, H.P., Havrdova, E., Selmaj, K.W., Margolin, D.H., Palmer, J., Oyuela, P.

“…Alemtuzumab is approved in over 30 countries for relapsing-remitting multiple sclerosis. In the 2-year, phase 3 CARE-MS II study (NCT00548405), alemtuzumab had…”
Get full text

Pegyliertes Interferon-beta 1a: Eine neue Therapieoption zur Behandlung der schubförmigen multiplen Sklerose by Leussink, V.I., Warnke, C., Tackenberg, B., Wiendl, H., Kieseier, B.C.

“…Zusammenfassung Die Pegylierung pharmakologischer Substanzen wurde in den 1970er Jahren als ein Verfahren entwickelt, um deren Wirkung zu verbessern und deren…”
Get full text

Leopold Ordenstein: on paralysis agitans and multiple sclerosis by Lehmann, H.C., Hartung, H.-P., Kieseier, B.C.

“…In 1868 the German Leopold Ordenstein (1835—1902) published in Paris a doctoral thesis in French language under the patronage of Jean-Martin Charcot…”
Get full text

Diagnostik der Multiplen Sklerose 2010 Revision der McDonald-Kriterien by Klotz, L., Gold, R., Hemmer, B., Korn, T., Zipp, F., Hohlfeld, R., Kieseier, B.C., Wiendl, H.

“…Zusammenfassung Im Jahr 2010 erfolgte die zweite Revision der McDonald-Kriterien für die Diagnose einer Multiplen Sklerose. Auf Basis der aktuellen…”
Get full text

Teriflunomid zur Behandlung der Multiplen Sklerose by Warnke, C., Meyer Zu Hörste, G., Menge, T., Stüve, O., Hartung, H.-P., Wiendl, H., Kieseier, B.C.

“…Zusammenfassung Aktuell werden Interferon-β-Präparate und Glatirameracetat als Basistherapeutika zur Behandlung der schubförmigen Multiplen Sklerose (MS)…”
Get full text

Cannabinoide zur symptomatischen Therapie der Multiplen Sklerose by Husseini, L., Leussink, V.I., Warnke, C., Hartung, H.-P., Kieseier, B.C.

“…Zusammenfassung Spastik stellt ein häufiges Problem im klinischen Verlauf von Patienten mit Multipler Sklerose dar. Trotz verschiedener symptomatischer…”
Get full text

Risikostratifizierung einer progressiven multifokalen Leukenzephalopathie unter Natalizumab: Empfehlungen zur JC-Virus-Serologie by Warnke, C., Adams, O., Hartung, H.P., Gold, R., Hemmer, B., Hohlfeld, R., Stangel, M., Zipp, F., Wiendl, H., Kieseier, B.C.

“…Zusammenfassung Die JC-Virus (JCV)-assoziierte progressive multifokale Leukenzephalopathie (PML) ist eine schwerwiegende unerwünschte Arzneimittelwirkung, die…”
Get full text